Multi Course: PG 2019

Introduction

The CME webinar course is provided by ENETS and based on the ENETS annual conference Postgraduate (PG) talks/webcasts from 2019. There have been held 11 talks, each resulting in a webinar of 30 min.

As UEMS/ACCME  are  accrediting 1 CME per 60 min e-learning, we provide here the whole selection of talks as webinars from which you can choose according to your specific interest.

You can choose two out of 11 topics. For each pair of chosen topics you can earn 1 European CME credit (ECMEC). 

Webinar aim

The aim is to provide learners with up-to-date and clinically relevant topics on NEN.

This multi course comprises 11 talks from the postgraduate course held in 2019.

To learn more about each topic and its presenter, please click on the learning objectives.

Webinar will include

Two postgraduate talks (learners can select any two from the 11 webinars on offer), webinar course material (slides and references), an assessment and evaluation.

Length of webinar(s)

60 minutes each

Date of webinar

Begin: XXX 2019

End: XXX 2021

Accreditation

1 European CME credit (ECMEC)

 

Disclosure

The webinar is free of advertising.

Target Audience

This webinar is intended for primary care physicians, physician assistants, and scientists in advanced clinical training (postgraduate) with an explicit interest in the treatment of gastroenteropatic neuroendocrine tumors.

Specialty fields include gastroenterology, oncology, endocrinology, pathology, as well as radiology, nuclear medicine and surgery, as there is a specific need for an interdisciplinary approach to neuroendocrine tumors.

Technical requirements

The webinar is easy to use and can be accessed via any internet-capable device (PC, Notebook, Tablet) on the Operating Systems Windows, MacOS, Linux, iOS and Android. The supported web browsers are Internet Explorer 9+, Microsoft Edge, Mozilla Firefox, Google Chrome and Apple Safari. All Browsers (except for Internet Explorer) are supported in the latest and second latest version.

 
Topic 01: Molecular Pathology of Neuroendocrine Neoplasms (NENs): Clinical Implications
Lecturer: Professor Dr. Aldo, Scarpa, ARC-NET Research Centre and Department of Pathology, Verona University, Italy

Learning Objectives

On successful completion of this activity, participants should be able to describe:

  • A summary of the anatomical, biological and clinical heterogeneity of gastroenteropancreatic and lung neuroendocrine neoplasms.
  • The main histological and biological differences between well-differentiated neuroendocrine tumors (carcinoids) and the more aggressive poorly-differentiated neuroendocrine carcinomas.
  • How genetic syndromes provided insights into sporadic neuroendocrine tumors biology.
  • How integrative genomics studies provided a first glance at the convergence of many low-frequency alterations into a limited number of pathways.
  • How mTOR pathway and cell cycle dysregulation is differently achieved in ileal and pancreatic neuroendocrine tumors.
  • The different ways through which chromatin remodelling is hijacked in pancreatic, lung and small intestinal NETs.
  • What is necessary in the next future to provide effective companion diagnostics and to enable informed precision therapy.
Topic 02: The Role of Nuclear Medicine in the Diagnosis of NENs: State-of-the-art and Future Perspectives
Lecturer: Dr. Aviral Singh, Zentralklinik Bad Berka, Germany

Learning Objectives

On successful completion of this activity, participants should be able to describe:

  • Scope of nuclear medicine for functional imaging of NEN
  • Currently available options for functional imaging of NEN
  • Role of dual – receptor based and metabolic imaging in NEN
  • Evolving role of somatostatin receptor antagonist imaging in NEN
  • Novel radionuclides under investigation for molecular imaging of NEN
  • Current and prospective developments of hardware and software for functional imaging
Topic 03: Follow-up of Resected Lung and GEP NENs: How Often, What and for How Long?
Lecturer: Professor Dr. Angela Lamarca, The Christie NHS Foundation Trust, Manchester, United Kingdom

Learning objectives

On successful completion of this activity, participants should be able to describe:

  • Understanding the importance of post-surgical follow-up for patients with resected neuroendocrine tumors
  • To understand the rationale behind the most appropriate imaging and biochemical follow-up tools and tests
  • To have an overview of current guidelines and recommendations for post-surgical resection
Topic 04: Towards parenchyma-sparing resections in bronchial and thymic NET
Lecturer: Prof. Pier Luigi Filosso, University of Torino, Italy, Department of Surgical Sciences, Unit of Thoracic Surgery

Learning objectives

On successful completion of this activity, participants should be able to describe:

  • The current surgical management of peripherally-located bronchial carcinoids
  • The current surgical management of central lesion
  • The role of lung parenchymal-sparing resections in bronchial NETs
  • The role of lymphadenectomy in bronchial NETs
  • The current surgical management of thymic NETs
  • The importance of extended resections in case of advanced diseases

 

Topic 05: Sequence of non-surgical management in advanced bronchial and thymic NET
Lecturer: Professor Martyn Caplin, Professor of Gastroenterology and Neuroendocrine Tumour Biology, Royal Free Hospital, London, NW3 2QG, UK

Learning objectives

On successful completion of this activity, participants should be able to describe:

  • Prognostic features of bronchial and thymic neuroendocrine neoplasms
  • the evidence for medical therapies in bronchial and thymic neuroendocrine neoplasms
  • how one might determine the best choice of therapy for an individual patient
  • Determination of where future clinical studies are required
Topic 06: Management of advanced medullary thyroid carcinoma
Lecturer: Professor Gregory Kaltsas, 1st Department of Propaupedic and Internal Medicine, National and Kapodistrian University of Athens, Greece

Learning objectives

On successful completion of this activity, participants should be able to describe.

  • Identify patients with advanced MTC that require initiation of systemic treatment
  • Utilise surgery and locoregional modalities in specific clinical settings
  • Understand the principles of currently available treatments and limitations
  • Familiarise with the safety and efficacy of targeted therapies (vandetanib, cabozantinib)
  • Consider available and evolving additional therapies
Topic 07: Mesenteric fibrosis: An unresolved mystery
Lecturer: Dr Dalvinder Mandair, Royal Free Hospital, London

Learning objectives

On successful completion of this activity, participants should be able to describe:

  • What is mesenteric fibrosis and be aware of the incidence
  • The clinical features associated with mesenteric fibrosis and some of the radiological findings
  • Predictors of the development of mesenteric fibrosis
  • Indications for surgery in patients with mesenteric fibrosis
  • Management of vascular complications of mesenteric fibrosis
  • Keys areas in the pathogenesis of mesenteric fibrosis
Topic 08: Clinical management of high grade GEP NENs
Lecturer: Professor Dr. Juan Valle, University of Manchester / The Christie ENETS Centre of Excellence, UK

Learning Objectives

On successful completion of this activity, participants should be able to:

  • Describe the current and planned classification of high-grade GEP NENs
  • Outline the known molecular signatures defining high-grade GEP NENs
  • Discuss the therapeutic aims of therapy in patients with high-grade GEP NENs
  • Detail the available evidence underpinning systemic therapy of high-grade GEP NENs
  • Discuss the areas of unmet need with respect to evidence and ongoing/future research
Topic 09: Impact of Established Systemic Treatment Options on Patient’s Symptoms & Quality of Life (QoL)
Lecturer: Dr. Simona Glasberg, MD
Head, Neuroendocrine Tumor Unit | ENETS Center of Excellence
Endocrinology & Metabolism Department | Division of Medicine
Hadassah-Hebrew University Medical Center | Ein Kerem, Jerusalem

Learning objectives

On successful completion of this activity, participants should be able to describe:

  • How to define Quality of Life (QoL) and Health Related Quality of Life (HRQoL) and how to measure it
  • What are they the NET patient specific HRQoL outcomes
  • The impact of specific therapies on NET patient HRQoL
Topic 10: Novel antiangiogenics in the field of NETs
Lecturer: Professor Eric Raymond, Paris Saint-Joseph Hospital, France

Learning objectives

On successful completion of this activity, participants should be able to understand:

  • the basic principles of tumor angiogenesis
  • the rationale of targeting angiogenesis in NETs
  • the efficacy of antiangiogenics in the clinic for the treatment of NETs
Topic 11: Predictive Biomarkers to Guide Therapy
Lecturer: Dr. Jaume Capdevila, University Hospital Vall d'Hebron / Department of Medical Oncology, Spain

Learning objectives

On successful completion of this activity, participants should be able to understand:

  • The prognostic and predictive biomarkers currently available in NENs field
  • The most useful predictive biomarkers used in clinical practice
  • A quick future perspective